Abstract
Background Cisplatin-induced nephrotoxicity still occurs despite the intensive hydration approach adapted to prevent its occurrence. Objective Evaluation of the effect of acetazolamide (ACTZ) on minimizing cisplatin-induced nephrotoxicity compared to mannitol when added to hydration regimen. Setting Nasser Institute Cancer Center (NICC), Cairo, Egypt. Method A total of 35 patients planned to receive cisplatin were divided into two groups: 20 patients received mannitol and 15 patients received ACTZ. Both groups received standard hydration measures as well for prevention of cisplatin-induced nephrotoxicity. Main outcome measure Patients’ kidney function was assessed using serum creatinine, creatinine clearance and blood urea nitrogen. Kidney injury was assessed using RIFLE criteria. Patients’ liver function tests and hematological parameters were also monitored. Results Patients in the mannitol group showed higher risk of developing kidney injury (30%) whereas those in the ACTZ group showed lower risk (8.9%), relative risk (RR) 0.269, 95% CI 0.108–0.815. No statistically significant difference occurred between the two groups concerning liver function tests or hematological parameters. Conclusion Use of ACTZ in addition to intensive hydration may have more beneficial effect on minimizing cisplatin-induced nephrotoxicity compared to mannitol plus intensive hydration approach. A large multicenter randomized clinical trials is recommended to confirm study results and to assess effect of ACTZ on tumor response.
Similar content being viewed by others
References
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins. 2010;2(11):2490–518.
Hartmann JT, Fels LM, Knop S, Stolt H, Kanz L, Bokemeyer C. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs. 2000;18(3):281–9.
Thomas Hartmann J, Lipp H-P. Toxicity of platinum compounds. Exp Opin Pharmacother. 2003;4(6):889–901.
Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334(2):115–24.
Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol. 2005;22(5):441–5.
Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 2009;86(4):396–402.
Shiraishi F, Curtis LM, Truong L, Poss K, Visner GA, Madsen K, et al. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am J Physiol Renal Physiol. 2000;278(5):F726–36.
Portilla D, Safar AM, Shannon ML, Penson RT. Cisplatin nephrotoxicity Uptodate (2015).
Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer. 1977;39(4):1357–61.
Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, et al. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS ONE. 2014;9(7):e101902.
Moon HH, Seo KW, Yoon KY, Shin YM, Choi KH, Lee SH. Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. World J Gastroenterol. 2011;17(30):3510–7.
Sato K, Watanabe S, Ohtsubo A, Shoji S, Ishikawa D, Tanaka T, et al. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. BMC Cancer. 2016;16:222.
De Jongh FE, Van Veen RN, Veltman SJ, De Wit R, Van der Burg ME, Van den Bent MJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer. 2003;88(8):1199–206.
Faig J, Haughton M, Taylor RC, D’Agostino RB, Whelen MJ, Porosnicu Rodriguez KA, et al. Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. Am J Clin Oncol. 2016;41(5):432–40.
Morgan KP, Buie LW, Savage SW. The Role of Mannitol as a Nephroprotectant in Patients Receiving Cisplatin Therapy. Ann Pharmacother. 2012;46(2):276–81.
Hayati F, Hossainzadeh M, Shayanpour S, Abedi-Gheshlaghi Z, Beladi Mousavi SS. Prevention of cisplatin nephrotoxicity. J Nephropharmacol. 2016;5(1):57–60.
Block KI, Gyllenhaal C. Commentary: the pharmacological antioxidant amifostine—implications of recent research for integrative cancer care. Integr Cancer Therapies. 2005;4(4):329–51.
Gopalakrishnan R, Murugesan A, Babu E, Sakthisekaran D. Protective role of vitamin E and acetazolamide in cisplatin-induced changes in lipid peroxidation and antioxidant enzyme levels in albino rats. J Clin Biochem Nutr. 1996;20(3):203–10.
Heidemann H, Gerkens J, Jackson E, Branch R. Attenuation of cisplatinum-induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide. Naunyn-Schmiedeberg’s Arch Pharmacol. 1985;329(2):201–5.
Heidemann HT, Gjessing L, Brune KH, Ohnhaus EE. The effect of acetazolamide and furosemide on lithium clearance and cisplatin nephrotoxicity in the rat. In: Bach PH, Lock EA, editors. Nephrotoxicity. Springer: US; 1989. p. 367–70.
Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
Bauer L. In: McGraw H, editor. Applied clinical pharmacokinetics. New York: Edical Publishing Division; 2001. p. 93–179.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care. 2004;8(4):R204–12.
Aronoff G, Bennett W, Berns J, Brier M, Kasbekar N, Mueller B, et al. Drug prescribing in renal failure dosing guidelines for adults and children. 5th ed. Philadelphia: American College of Physicians; 2007.
Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1998;34(10):1522–34.
Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014;2014:17.
Prasaja Y, Sutandyo N, Andrajati R. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia. Asian Pac J Cancer Prev APJCP. 2015;16(3):1117–22.
Osman NM, Copley MP, Litterst CL. Effects of the diuretics mannitol or acetazolamide on nephrotoxicity and physiological disposition of cisplatin in rats. Cancer Chemother Pharmacol. 1984;13(1):58–62.
Heidemann HT, Hoffmann K, Inselmann G. Long-term effects of acetazolamide and sodium chloride loading on cisplatin nephrotoxicity in the rat. Eur J Clin Invest. 1990;20(2):214–8.
Osman N, Copley M, Litterst C. Amelioration of cisplatin-induced nephrotoxicity by the diuretic acetazolamide in F344 rats. Cancer Treat Rep. 1983;68(7–8):999–1004.
Santoso JT, Lucci JA, Coleman RL, Schafer I, Hannigan E. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 2003;52(1):13–8.
Pingle SC, Mishra S, Marcuzzi A, Bhat SG, Sekino Y, Rybak LP, et al. Osmotic diuretics induce adenosine A1 receptor expression and protect renal proximal tubular epithelial cells against cisplatin-mediated apoptosis. J Biol Chem. 2004;279(41):43157–67.
Morgan KP, Snavely AC, Wind LS, Buie LW, Grilley-Olson J, Walko CM, et al. Rates of renal toxicity in cancer patients receiving cisplatin with and without mannitol. Ann Pharmacother. 2014;48(7):863–9.
Muraki K, Koyama R, Honma Y, Yagishita S, Shukuya T, Ohashi R, et al. Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer. J Thorac Dis. 2012;4(6):562–8.
Al-Sarraf M, Fletcher W, Oishi N, Pugh R, Hewlett JS, Balducci L, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep. 1982;66(1):31–5.
Lehane D, Winston A, Gray R, Daskal Y. The effect of diuretic pre-treatment on clinical, morphological and ultrastructural cis-platinum induced nephrotoxicity. Int J Radiat Oncol Biol Phys. 1979;5(8):1393–9.
Ostrow S, Egorin MJ, Hahn D, Markus S, Aisner J, Chang P, et al. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep. 1981;65(1–2):73–8.
Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH. High dose Cis-platinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis. Cancer. 1977;39(4):1372–81.
Goren MP, Wright RK, Horowitz ME. Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother Pharmacol. 1986;18(1):69–73.
Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European society of clinical pharmacy special interest group on cancer care. Cancer Chemother Pharmacol. 2008;61(6):903–9.
Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist. 2017;22(5):609–19.
Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, Sternson LA. Clinical kinetics of intact cisplatin and some related species. Clin Pharmacol Ther. 1981;29(5):658–64.
Availability of data and materials
The datasets generated during and/or analyzed during the current study are available from the corresponding author on request.
Funding
None.
Conflicts of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
El Hamamsy, M., Kamal, N., Bazan, N.S. et al. Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study. Int J Clin Pharm 40, 1539–1547 (2018). https://doi.org/10.1007/s11096-018-0677-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-018-0677-x